ArticleMolecular cancer2024

Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma.

Junjie Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.